Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: the Debate Continues

World Journal of Gastrointestinal Oncology

Volumn 6, Issue 12, 2014, Pages 438-440

  Felice, Francesca De ^a   Musio, Daniela ^a   Izzo, Luciano ^a   Tombolini, Vincenzo ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

Chemoradiotherapy; Debate; Locally advanced disease; Neoadjuvant; Rectal cancer

Indexed keywords

EID: 84938751579     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v6.i12.438     Document Type: Article

References (7)

1. 1 Musio D, De Felice F, Bulzonetti N, Guarnaccia R, Caiazzo R, Bangrazi C, Raffetto N, Tombolini V. Neoadjuvantintensified treatment for rectal cancer: time to change? World J Gastroenterol 2013; 19: 3052-3061 [PMID: 23716984 DOI: 10.3748/wjg.v19.i20.3052]
2. 2 Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13: 679-687 [PMID: 22627104]
3. 3 André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116 [PMID: 19451431 DOI: 10.1200/JCO.2008.20.6771]
4. 4 Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29: 2773-2780 [PMID: 21606427 DOI: 10.1200/ JCO.2010.34.4911]
5. 5 Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Montoto- Grillot C, Conroy T. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28: 1638-1644 [PMID: 20194850 DOI: 10.1200/JCO.2009.25.8376]
6. 6 Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27: 5124-5130[PMID: 19770376 DOI: 10.1200/JCO.2009.22.0467]
7. 7 Hamid A, Shapiro JD, McMurrick P, Bell S, Porter I, Carne P, Haydon AM. Do patients achieving pathologic completeresponse (pCR) following neoadjuvant treatment for locally advanced rectal cancer (LARC) need adjuvant chemotherapy? 2014 ASCO Annual Meeting. J Clin Oncol 2014; 32: 5s